The inhibition of SIRT2 in lupus‐prone mice reduces IL‐17A levels and ameliorates disease symptoms, demonstrating a direct link between Th17 cell activity and SLE pathogenesis [136]. This evidence concerns the gene IL17A and systemic lupus erythematosus.